SEARCH

SEARCH BY CITATION

References

  • 1
    Brosnahan MM, Paradis MR. Assessment of clinical characteristics, management practices, and activities of geriatric horses. J Am Vet Med Assoc 2003;223:99103.
  • 2
    Van Der Kolk JH, Heinrichs M, Van Amerongen JD, et al. Evaluation of pituitary gland anatomy and histopathologic findings in clinically normal horses and horses and ponies with pituitary pars intermedia adenoma. Am J Vet Res 2004;65:17011707.
  • 3
    Orth DN, Holscher MA, Wilson MG, et al. Equine Cushing's disease: Plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests. Endocrinol 1982;110:14301441.
  • 4
    Millington WR, Dybdal NO, Dawson R Jr, et al. Equine Cushing's disease: Differential regulation of β-endorphin processing in tumors of the intermediate pituitary. Endocrinol 1988;123:15981604.
  • 5
    Donaldson MT, LaMonte BJ, Morresey P, et al. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease). J Vet Intern Med 2002;16:742746.
  • 6
    Schott HC, Coursen CL, Eberhart SW, et al. The Michigan Cushing's Project. In: Proceedings of the 47st Annual Convention of the American Association of Equine Practitioners 2001;2224.
  • 7
    Perkins GA, Lamb S, Erb HN, et al. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide. Equine Vet J 2002;34:679685.
  • 8
    McFarlane D, Dybdal N, Donaldson MT, et al. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J Neuroendocrinol 2005;17:7380.
  • 9
    Goudreau JL, Falls WM, Lookingland KJ, et al. Periventricular-hypophysial dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland. Neuroendocrinol 1995;62:147154.
  • 10
    Saiardi A, Borrelli E. Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice. Mol Endocrinol 1998;12:11331139.
  • 11
    Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 2003;39:889909.
  • 12
    McGeer PL, Itagaki S, Boyes BE, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:12851291.
  • 13
    Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: Role for cytokines. Curr Pharm Des 2005;11:9991016.
  • 14
    Barcia C, Sanchez BA, Fernandez-Villalba E, et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 2004;46:402409.
  • 15
    Bronstein DM, Perez-Otano I, Sun V, et al. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res 1995;704:112116.
  • 16
    Gao HM, Jiang J, Wilson B, et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson's disease. J Neurochem 2002;81:12851297.
  • 17
    Kurkowska-Jastrzebska I, Litwin T, Joniec I, et al. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int Immunopharmacol 2004;4:13071318.
  • 18
    Gruver A, Hudson L, Sempowski G. Immunosenescence of ageing. J Pathol 2007;211:144156.
  • 19
    Conde JR, Streit WJ. Microglia in the aging brain. J Neuropathol Exp Neurol 2006;65:199203.
  • 20
    McFarlane D, Donaldson MT, McDonnell SM, et al. Effects of season and sample handling on measurement of plasma alpha-melanocyte-stimulating hormone concentrations in horses and ponies. Am J Vet Res 2004;65:14631468.
  • 21
    Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, eds. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press; 2000:365386.
  • 22
    Vick MM, Adams AA, Murphy BA, et al. Relationships among inflammatory cytokines, obesity, and insulin sensitivity in the horse. J Anim Sci 2007;85:11441155.
  • 23
    Pawelec G. Immunity and ageing in man. Exp Gerontol 2006;41:12391242.
  • 24
    Rink L, Cakman I, Kirchner H. Altered cytokine production in the elderly. Mech Ageing Dev 1998;102:199209.
  • 25
    Jerin A, Pozar-Lukanovic N, Sojar V, et al. Balance of pro- and anti-inflammatory cytokines in liver surgery. Clin Chem Lab Med 2003;41:899903.
  • 26
    Gabriel P, Cakman I, Rink L. Overproduction of monokines by leukocytes after stimulation with lipopolysaccharide in the elderly. Exp Gerontol 2002;37:235247.
  • 27
    Leng S, Xue QL, Huang Y, et al. Total and differential white blood cell counts and their associations with circulating interleukin-6 levels in community-dwelling older women. J Gerontol A Biol Sci Med Sci 2005;60:195199.
  • 28
    Eylar EH, Lefranc CE, Yamamura Y, et al. HIV infection and aging: Enhanced interferon- and tumor necrosis factor-alpha production by the CD8+. BMC Immunol 2001;2:10.
  • 29
    Prior C, Knight RA, Herold M, et al. Pulmonary sarcoidosis: Patterns of cytokine release in vitro. Eur Respir J 1996;9:4753.
  • 30
    Schott HC. Pituitary pars intermedia dysfunction: Equine Cushing's disease. Vet Clin North Am Equine Pract 2002;18:237270.
  • 31
    Van Der Kolk HH, Kalsbeek HC, Van Garderen E, et al. Equine pituitary neoplasia: A clinical report of 21 cases (1990–1992). Vet Rec 1993;133:594597.
  • 32
    Hillyer MH, Taylor FRG, Mair TS, et al. Diagnosis of hyperadrenocorticism in the horse. Equine Vet Educ 1992;4:131134.
  • 33
    Taylor AW. The immunomodulating neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. J Neuroimmunol 2005;162:4350.
  • 34
    D'Acquisto F, Ianaro A. From willow bark to peptides: The ever widening spectrum of NF-kappaB inhibitors. Curr Opin Pharmacol 2006;6:387392.